EUCTR2017-005006-35-GR进行中（未招募）1 期
ong Term Extension Trial of setmelanotide (RM-493) for patients who havecompleted a trial of Setmelanotide for the treatment of obesity associated withgenetic defects upstream of the MC4 receptor in the leptin-melanocortinpathway
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients aged 2 or older that have completed participation on active drug and demonstrated adequate safety and meaningful clinical benefit (efficacy) in a previous setmelanotide study for obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway.Meaningful clinical benefit is defined as follows:
- •Patients up to 18 years of age that have completed participation on
- •active drug and demonstrated adequate safety and at least 2% body
- •mass index (BMI) reduction or reduction in BMI Z score of 0.2
- •compared to baseline.
- •Patients over 18 years of age should show reduction of 3% weight
- •compared to baseline.
- •2. Study participant and/or parent or guardian is able to communicate well with the investigator, to understand and comply with the requirements of the study, and to understand and sign the written informed consent/assent.
- •The patient must assent/consent to participate in the trial.
- •3. Patient must meet one of the following requirements:
- •If a female of childbearing potential, defined as fertile, following
- •menarche and until becoming post-menopausal unless permanently
- •sterile (hysterectomy, bilateral salpingectomy, or bilateral
- •oophorectomy), must use a highly effective form of contraception as
- •outlined in the protocol
- •If a female of non-childbearing potential, defined as permanently
- •sterile (status post hysterectomy, bilateral oophorectomy, or bilateral
- •salpingectomy) or post-menopausal for at least 12 months (and
- •confirmed with a screening FSH level in the post-menopausal laboratory
- •range), contraception is not required during the study. - Any female
- •participant in this latter category of having failed to Younger female
- •patients who have not reached menarche upon study entry, will be
- •assessed for Tanner staging and at first menarche will be required to
- •comply with contraception requirements and pregnancy testing as
- •outlined in the protocol.
- •If a male with female partner(s) of childbearing potential, must agree
- •to a double barrier method if they become sexually active during the
- •study. Furthermore, male patients must not donate sperm during and for
- •90 days following their participation in the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 150
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 83
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 3
排除标准
- •1.Pregnant and/or breastfeeding women
- •2.Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions (excluding non-invasive basal or squamous cell lesion), determined as part of a screening comprehensive skin evaluation performed by a qualified dermatologist. Any concerning lesions identified during the screening period will be biopsied and results known to be benign prior to enrollment. If the pre-treatment biopsy results are of concern, the patient may need to be excluded from the study.
- •3. Patient is, in the opinion of the Study Investigator, not suitable to participate in the study.
- •In addition, any patient who experiences a gap in treatment of at least one month between completing the Index study and Screening for this study, should have the following exclusion criteria evaluated:
- •4. Current, clinically significant disease, if severe enough to interfere with the study and/or would confound the results. Any such patients should be discussed with the Sponsor prior to inclusion
- •5. Diagnosis of schizophrenia, bipolar disorder, personality disorder or other Diagnostic and Statistical Manual of Mental Disorders (DSM-III) disorders that the investigator believes will interfere significantly with study compliance.
- •6. A Patient Health Questionnaire-9 (PHQ-9) score of = 15.
- •7. Any suicidal ideation of type 4 or 5 on the Columbia Suicide Severity Rating Scale (CSSRS). Any lifetime history of a suicide attempt, or any suicidal behavior in the last month.
- •Note: Patients who are unable to complete the PHQ-9 or C-SSRS due to significant neurocognitive defects may be enrolled in the study, as long as in the opinion of the Primary Investigator there are no clinical signs or symptoms of suicidal behavior.
- •8. History of significant liver disease or liver injury, or a current liver assessment due to abnormal liver tests (as indicated by abnormal liver function tests, alanine transaminase [ALT], aspartate transaminase [AST], alkaline phosphatase, or serum bilirubin >1.5× the upper limit of normal [ULN] for any of these tests) for an etiology other than nonalcoholic fatty liver disease (NAFLD). Thus, any underlying etiology besides NAFLD, including diagnosed non-alcoholic steatohepatitis (NASH), other causes of hepatitis, or history of hepatic cirrhosis is exclusionary, but the presence of NAFLD is not be exclusionary.
- •9. Moderate to severe renal dysfunction as defined by a glomerular filtration rate (GFR)
- •<30 mL/min/1.73 m2.
- •10. History or close family history (parents or siblings) of skin cancer or melanoma (not including non-invasive/infiltrative basal or squamous cell lesion), or patient history of ocular-cutaneous albinism.
研究者
相似试验
进行中（未招募）
1 期
ong Term Extension Trial of setmelanotide for patients who havecompleted a trial of Setmelanotide for the treatment of obesity associated withgenetic defects.Patients with obesity caused by genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway. Some rare genetic disorders include:obesity, including: Leptin Receptor (LepR) Deficiency Obesity POMC Heterozygous Deficiency Obesity POMC Epigenetic Deficiency Obesity Bardet-Biedl syndromeAlström syndromeEUCTR2017-005006-35-ESRhythm Pharmaceuticals, Inc.150
进行中（未招募）
1 期
ong Term Extension Trial of setmelanotide for patients who havecompleted a trial of Setmelanotide for the treatment of obesity associated withgenetic defects.EUCTR2017-005006-35-GBRhythm Pharmaceuticals, Inc.150
招募中
3 期
ong Term Extension Trial of setmelanotide (RM-493) for patients who have completed a trial of Setmelanotide for the treatment of obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathwaygenetic mutation10003018ObesityNL-OMON54784RHYTHM Pharmaceuticals14
进行中（未招募）
1 期
ong Term Extension Trial of setmelanotide (RM-493) for patients who have completed a trial of Setmelanotide for the treatment of obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathwayTreatment of obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathwayEUCTR2017-005006-35-FRRhythm Pharmaceuticals, Inc.100
进行中（未招募）
1 期
ong Term Extension Trial of setmelanotide for patients who havecompleted a trial of Setmelanotide for the treatment of obesity associated with genetic defectsPatients with obesity caused by genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway. Human Genetics studies have identified several diseases that are the result of genetic defects affecting the MC4R pathway, for example:•POMC deficiency obesity due to mutations in the POMC gene•PCSK1 deficiency due to mutations in the PCSK1 gene•LEPR deficiency obesity due to mutations in the LEPR gene•Bardet-Biedl syndrome•Alström syndromeEUCTR2017-005006-35-NLRhythm Pharmaceuticals, Inc.109